WaveMan
WaveMan · Company
SONX · Sonendo, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SONX Sonendo (SONX) Insider Trading, Ownership & Congress Trades

Medical Devices · Dental equipment & supplies · CIK 0001407973
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Sonendo insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Sonendo, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Bergheim Bjarne
President and CEO
SELL
2024-06-24 SECtraded 2024-06-21
43,240
$3.9K
-91.5%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (11 buys, 8 sales), the last on May 3, 2024.
  • -55.4% median (-52.1% mean) 90-day return after 11 previous buys.
  • The trade is 2.3% of the 1,888,518 shares held after it.
  • 2 other insiders sold within 30 days.
Insider activity: President and CEO Bergheim Bjarne sold about $3.9K of SONX on Jun 21, 2024; 2 other insiders sold within 30 days.
Chen Roy T
Chief Talent Officer
SELL
2024-06-24 SECtraded 2024-06-20
8,510
$766
-91.5%
Context
  • 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on May 3, 2024.
  • The trade is 3.6% of the 233,777 shares held after it.
  • 2 other insiders sold within 30 days.
Insider activity: Chief Talent Officer Chen Roy T sold about $766 of SONX on Jun 20, 2024; 2 other insiders sold within 30 days.
McGaugh John P.
SELL
2024-05-28 SECtraded 2024-05-23
10,901
$981
-93.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 22, 2024.
  • The trade is 3.1% of the 352,896 shares held after it.
  • 3 other insiders sold within 30 days.
Insider activity: Insider McGaugh John P. sold about $981 of SONX on May 23, 2024; 3 other insiders sold within 30 days.
McGaugh John P.
BUY
2024-05-23 SECtraded 2024-05-22
116,500
$11.7K
-92.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 32.0% of the 363,797 shares held after it.
  • 2 other insiders bought within 30 days.
Insider activity: Insider McGaugh John P. bought about $11.7K of SONX on May 22, 2024; 2 other insiders bought within 30 days.
BERGHEIM OLAV
Director
BUY
2024-05-17 SECtraded 2024-05-16
520,000
$52.0K
-93.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 15, 2023.
  • -23.1% median (-19.4% mean) 90-day return after 3 previous buys.
  • The trade is 26.8% of the 1,941,373 shares held after it.
  • 2 other insiders bought within 30 days.
Insider activity: Director BERGHEIM OLAV bought about $52.0K of SONX on May 16, 2024; 2 other insiders bought within 30 days.
108 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 103 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-13.1% year over year
below 88% of Medical Devices
Margin
-88.4% net margin
below 79% of Medical Devices
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SONX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+212.2%12M
-95%+57%+209%+361%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SONX: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in SONX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SONX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

SONX financials

Revenue growth
-13.1%
XBRL, annual
Net margin
-88.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
-$24.8M
operating cash flow minus capex, 2024-01-01 to 2024-12-31
Debt to equity
2.78x
long-term 2024-12-31 plus current 2024-12-31; equity 2024-12-31
Cash flow to debt
-1.71x
TTM operating cash flow over long-term 2024-12-31 plus current 2024-12-31
Return on equity
-166.8%
TTM net income over average of 2023-12-31 and 2024-12-31
Return on assets
-51.2%
TTM net income over average of 2023-12-31 and 2024-12-31
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-108.4%
operating income (EBIT proxy) over average of 2023-12-31 and 2024-12-31 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$4.8M
market value at close 2026-10-26 on 2025-03-12 shares, plus long-term 2024-12-31 plus current 2024-12-31, minus cash 2024-12-31
FCF yield
-4,536%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2024-122024-092024-062024-03
Revenue$33.2M$36.5M$38.9M$41.6M
Gross profit$11.8Mn/an/an/a
Operating income-$29.4Mn/an/an/a
Net income-$28.0Mn/an/an/a
EPS (diluted)-59.03n/an/an/a
Operating cash flow-$24.7Mn/an/an/a
Cash$10.2M$13.1M$15.7M$18.6M
Long-term debt$3.6M$6.1M$8.5M$10.9M
SEC XBRL, fiscal years, as known on 2026-10-28

SONX Stock Sonar score 4/7 axes

Find similar shapesCompare

SONX ranks highest on risk and compliance (99th percentile) and profitability (21st), and lowest on growth (12th), among Medical Devices peers.

Profitability
21
Inputs
  • Return on equity-166.8% · 17 pct, sector of 183
  • Return on assets-51.2% · 30 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-108.4% · 17 pct, sector of 188
Financial health
18
Inputs
  • Debt to equity2.78x · 11 pct, sector of 159
  • Cash flow to debt-1.71x · 26 pct, sector of 150
Growth
12
Inputs
  • Revenue growth, YoY-13.1% · 12 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
100
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies